Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics

BURLINGAME, Calif., Sept. 14, 2017 -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Five Prime Therapeutics, Inc. (NASDAQ:FPRX). The non-exclusive license grants Five Prime rights to use the AlivaMab Mouse for antibody drug discovery and development.

“Ablexis is pleased to add Five Prime to the list of leading biopharmaceutical companies that are using the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The AlivaMab Mouse is already being used by the majority of the world’s top 15 pharmaceutical companies, more than any other next generation antibody discovery platform. Now, with newly added licensing flexibility, Ablexis continues expanding the licensing of the AlivaMab Mouse for the rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability.”

About Ablexis, LLC

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses. More information can be found by visiting the Company’s website at www.ablexis.com.

Ablexis Corporate Contact:                                                          
Ablexis, LLC                                                                                 
Larry Green, (415) 967-1220                                                        
[email protected]                                                                            

Ablexis Media Contact:
Red House Communications
Denise Powell, (510) 703-9491
[email protected]